Literature DB >> 30136248

The cutting-edge technologies of siRNA delivery and their application in clinical trials.

Kyuri Lee1, Bora Jang1, You-Ri Lee1, Eun-Young Suh1, Ji-Seon Yoo1, Mi-Jin Lee1, Joo-Young Lee1, Hyukjin Lee2.   

Abstract

siRNA therapeutics allows precise regulation of disease specific gene expression to treat various diseases. Although gene silencing approaches using siRNA therapeutics shows some promising results in the treatment of gene-related diseases, the practical applications has been limited by problems such as inefficient in vivo delivery to target cells and nonspecific immune responses after systemic or local administration. To overcome these issues, various in vivo delivery platforms have been introduced. Here we provide an overview for three different platform technologies for the in vivo delivery of therapeutic siRNAs (siRNA-GalNAc conjugate, SAMiRNA technology, and LNP-based delivery method) and their applications in the treatment of various diseases. In addition, a brief introduction to some rare diseases and mechanisms of siRNA therapeutics-mediated treatment is described.

Entities:  

Keywords:  Clinical trials; Drug delivery; Rare diseases; siRNA therapeutics

Mesh：

Substances：

Year:  2018        PMID： 30136248     DOI： 10.1007/s12272-018-1069-4

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN： 0253-6269            Impact factor:   4.946


  9 in total

Review 1.  Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias.

Authors:  Clarice Gareri; Alberto Polimeni; Salvatore Giordano; Laura Tammè; Antonio Curcio; Ciro Indolfi
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

Review 2.  Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.

Authors:  Yonghan He; Sajid Khan; Zhiguang Huo; Dongwen Lv; Xuan Zhang; Xingui Liu; Yaxia Yuan; Robert Hromas; Mingjiang Xu; Guangrong Zheng; Daohong Zhou
Journal:  J Hematol Oncol       Date:  2020-07-27       Impact factor: 17.388

Review 3.  Noncoding RNAs in cancer therapy resistance and targeted drug development.

Authors:  Wen-Tao Wang; Cai Han; Yu-Meng Sun; Tian-Qi Chen; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2019-06-07       Impact factor: 17.388

4.  Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA.

Authors:  Hongjia Zhang; Ke Men; Congbin Pan; Yan Gao; Jingmei Li; Sibei Lei; Guonian Zhu; Rui Li; Yuquan Wei; Xingmei Duan
Journal:  Int J Nanomedicine       Date:  2020-12-07

Review 5.  NGAL as a Potential Target in Tumor Microenvironment.

Authors:  Elvira Crescenzi; Antonio Leonardi; Francesco Pacifico
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

Review 6.  Directing the Way-Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery.

Authors:  Ricarda Carolin Steffens; Ernst Wagner
Journal:  Pharm Res       Date:  2022-09-15       Impact factor: 4.580

Review 7.  Degradation of proteins by PROTACs and other strategies.

Authors:  Yang Wang; Xueyang Jiang; Feng Feng; Wenyuan Liu; Haopeng Sun
Journal:  Acta Pharm Sin B       Date:  2019-08-13       Impact factor: 11.413

Review 8.  Noncoding RNAs in Glioblastoma: Emerging Biological Concepts and Potential Therapeutic Implications.

Authors:  Uswa Shahzad; Stacey Krumholtz; James T Rutka; Sunit Das
Journal:  Cancers (Basel)       Date:  2021-03-28       Impact factor: 6.639

9.  Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia.

Authors:  Sung-Il Yun; Sang-Kyu Lee; Eun-Ah Goh; Oh Seung Kwon; Woorim Choi; Jangseon Kim; Mi Sun Lee; Soon Ja Choi; Seung Sik Lim; Tae Kee Moon; Sin Hae Kim; Keeyeol Kyong; Gaewon Nam; Han-Oh Park
Journal:  Sci Rep       Date:  2022-01-31       Impact factor: 4.996
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.